ARDX Ardelyx Inc.

2.54
0  0%
Previous Close 2.54
Open 2.53
Price To Book 1.73
Market Cap 159,005,125
Shares 62,600,443
Volume 36,586
Short Ratio
Av. Daily Volume 131,039

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 12, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 4Q 2019.
Tenapanor - PHREEDOM
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3 data due 3Q 2019.
Tenapanor - AMPLIFY
Hyperphosphatemia - adjunctive therapy to phosphate binders

Latest News

  1. Does The Ardelyx, Inc. (NASDAQ:ARDX) Share Price Tend To Follow The Market?
  2. Is Ardelyx Inc (ARDX) A Good Stock To Buy?
  3. Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
  4. Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You
  5. Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
  6. Ardelyx: 1Q Earnings Snapshot
  7. Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
  8. Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
  9. What's in the Cards for Axon Enterprise (AAXN) Earnings?
  10. If You Had Bought Ardelyx (NASDAQ:ARDX) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today
  11. East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?
  12. Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
  13. Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
  14. Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
  15. An Examination Of Ardelyx, Inc. (NASDAQ:ARDX)
  16. Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
  17. Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
  18. Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
  19. Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount
  20. Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock?